The Viral Research and Experimental Medicine Centre @ SingHealth Duke-NUS (ViREMiCS) was established in 2017, and is the first core unit under the Infectious Disease Research Institute (IDRI). ViREMiCS aims to accelerate the clinical translation of vaccines and therapeutics by working with academia and industry partners to develop molecular tools that accurately assess the safety and efficacy of vaccines and therapeutics. Furthermore, adaptive experimental and clinical trial design enabling biological effects to be tested in parallel, rather than sequentially, can be deployed to further truncate the clinical development timeline. Current projects include clinical trials with vaccines or therapeutics against dengue virus, Zika virus, and yellow fever virus.
How we can help: • Objective tools to assess outcomes of early phase clinical trials• Guide down-selection of candidates to avoid unnecessary spending and late-stage failures• Bench to bedside translation of infectious disease therapeutics and vaccines in a timely and affordable manner.
Vision: To develop a world-class viral and experimental medicine research centre that supports the development and licensing of therapeutics and vaccines through the use of state-of-the-art technologies.
Mission: To integrate cutting edge research in Duke-NUS with SingHealth and to optimise the translation of bench to bedside medicine to promote health and improve health outcomes.
